The global conjugate vaccine market is anticipated to grow with the CAGR of 13.4% during the forecast period 2018-2023. Conjugate vaccines are similar to recombinant vaccines manufactured by the combination of two different components. Conjugate vaccines, however, are made by pieces from the coats of bacteria. These coats are chemically linked to a carrier protein, and the combination is used as a vaccine. Conjugate vaccines are used to create a more powerful, combined immune response from infectious diseases. The vaccines currently in use for children against pneumococcal bacterial infections are made using this technique. Haemophilus influenza type B (Hib) Vaccine, pneumococcal vaccine and meningococcal vaccine are some of the examples of conjugate vaccines.
The factors fuelling the growth of the conjugate vaccine market includes the increasing demand of meningococcal vaccines and pneumococcal. The increasing prevalence of infectious disease and rising awareness is estimated to boost the growth of the market. According to the U.S. National Library of Medicine, National Institutes of Health, the highest mortality cases reported were due to vaccine preventable diseases. High-income countries accounting for 87% of the population of have pneumococcal conjugate vaccines in their immunization schedules, whereas only 2% had pneumococcal conjugate vaccines in their immunization schedules among the total population of low-income countries.
The global conjugate vaccine market is segmented on the basis of product type, disease and pathogen type and patient type. On the basis of product type, the global conjugate vaccine market is bifurcated into multivalent conjugate vaccines and monovalent conjugate vaccines. The monovalent conjugate vaccines segment is one of the largest segment due to the high awareness and high-quality vaccines provided by key players. On the basis of disease, the global conjugate vaccine market can be segmented into meningococcal, diphtheria tetanus pertussis, influenza, pneumococcal, and others. On the basis of pathogen type, the global conjugate vaccine market segmented into combination conjugate vaccine, viral conjugate vaccine, and bacterial conjugate vaccine. On the basis of patient type, the market segmented into adult conjugate vaccine and pediatrics conjugate vaccine. The pediatrics conjugate vaccine segment has a potential market due to the high prevalence of infectious diseases among children.
Companies contributing to the growth of the global conjugate market include Serum Institute of India Pvt. Ltd., Sanofi Pasteur, Pfizer, Inc., Novartis AG, Neuron Biotech, Merck & Co., Inc., and GlaxoSmithKline plc. CSL Behring, Biological E, and Bharat Biotech and others.
The global conjugate vaccine market can be segmented geographically into, North America, Asia Pacific, Europe and rest of the world. North America is expected to be the most attractive market for conjugate vaccine during the forecast period, due to rise in demand for pneumococcal, meningococcal vaccines, and other conjugate vaccines. Asia Pacific is projected to increase during the forecast period owing to increasing immunization initiatives by organizations such as GAVI and World Health Organization in emerging economies such as India and China. Increasing focus of major players on the market in India and governmental initiatives for infectious diseases are likely to fuel the demand for the conjugate vaccines in the region.
The market study of conjugate vaccines market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
- Financial reports of companies involved in the market
- Authentic Public Databases
- Whitepapers, research-papers and news blogs
- Company websites and their product catalogue.
- Supplier Websites such as Alibaba, amazon for pricing analysis.
The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
- Global conjugate vaccine market by type
- Global conjugate vaccine market by
- Global conjugate vaccine market by immune response type
- Global conjugate vaccine market by disease
THE REPORT COVERS:
- Comprehensive research methodology of global conjugate vaccine market.
- This report also includes detailed and extensive market overview with analyst insights & key market trends.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global conjugate vaccine market.
- Insights about market determinants which are stimulating the global conjugate vaccine market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.